Directorate Change

Lisa Anson

Lisa Anson has been appointed as Non-Executive Director of the Company with effect from 1 October 2025.

Lisa is currently Chief Executive Officer of Redx Pharma limited, a UK based, privately held clinical-stage biotech business; a position she held when Redx was publicly listed on AIM. In addition, she is a Supervisory Board Member for Apoplex Medical Technologies GmBH, a private German company and is an elected Board Member of the UK BioIndustry Association (BIA). She was previously a Board Member and then Chair at the Association of the British Pharmaceutical Industry (ABPI).

Lisa's career spans almost 30 years in the pharmaceutical and Biotech industry including more than twenty years at AstraZeneca Plc. She has extensive global leadership and commercial experience, including several USA based roles and most recently was Country President for the UK and Ireland.

On appointment, Lisa will join the Audit Committee, Remuneration Committee and Nomination Committee of Porvair.

Porvair confirms that there are no further matters in relation to Lisa Anson's appointment to be disclosed pursuant to the requirements of paragraph 6.4.8 of the Listing Rules of the UK Listing Authority.

Sally Martin

Having completed 9 years as a Non-Executive Director at Porvair, Sally Martin will retire from the Board on 4 November 2025.

Sheena Mackay

Following Sally's retirement, Sheena Mackay will be appointed Senior Independent Director of the Board and the Non-Executive Director responsible for employee engagement, in addition to her role as Chair of the Remuneration Committee.